Skip to content

RapidFRET Oral Fluid Assay for Cocaine, Calibrator Set, Control Set

by Biophor Diagnostics, Inc.

510(k) K142129

Active United States

510(k)

Valid until

No expiry

510(k) clearance is not time-limited

FDA recalls

None found

in data synced 22 Oct 2026

Documents

Trust

Unverified

Registry data, not yet checked by deviCERTS. Source FDA 510(k), synced 22 Oct 2026. What this means

Regulatory status

as of registry sync 22 Oct 2026

RegionAuthorizationNumberDateStatus
United StatesFDA 510(k)SESE Substantially Equivalent · Traditional NumberK142129 Date24 Jul 2015ClearedStatusActive

Recalls

0 recalls · FDA

No FDA recalls found in the data synced 22 Oct 2026.

Coverage

1 jurisdiction

United States of America
  • Active
  • Expiring
  • Withdrawn
  • Listed
  • Not covered

United States — FDA 510(k) Active

Specification

510(k)

Full name
Rapidfret Oral Fluid Assay for Cocaine, Rapidfret Oral Fluid Cocaine Calibrator Set, Rapidfret Oral Fluid Cocaine Control Set
510(k) Number
FDA Product Code
DIO
Device Class
Class II
Regulation
21 CFR Part 862.3250
Advisory Committee
Clinical Toxicology
FDA Decision
SESE Substantially Equivalent

Overview

AI-generated summary, 1 Oct 2026

Written by a language model from registry data. Not verified by deviCERTS or the manufacturer. The registry data above is the record.

The RapidFRET Oral Fluid Assay for Cocaine is an enzyme immunoassay designed to detect cocaine and its metabolites in human oral fluid. This homogeneous time-resolved fluorescence assay employs competitive binding between an antibody labeled with an acceptor fluorophore and a donor fluorophore conjugated to the drug, enabling rapid and sensitive detection of cocaine presence.

The device is intended for use in central laboratories and operates on the RapidFRET Integrated Workstation. Supplied as a ready-to-use system, it includes a calibrator set and control set for validation. The assay is classified as a Class II medical device under FDA regulations (21 CFR 862.3250) and holds a 510(k) clearance (K142129) for substantial equivalence. No MRI safety or sterility specifications are provided, and usage is limited to single-use applications as per standard immunoassay protocols.

Other devices from Biophor Diagnostics, Inc.

Questions

AI-generated answers, 1 Oct 2026

Written by a language model from registry data. Not verified by deviCERTS or the manufacturer. The registry data above is the record.

  • What is the RapidFRET Oral Fluid Assay for Cocaine used for?

    The RapidFRET Oral Fluid Assay for Cocaine is an enzyme immunoassay designed to detect cocaine and its metabolites in human oral fluid. It uses competitive binding between an antibody labeled with a donor fluorophore and a cocaine conjugate labeled with an acceptor fluorophore, enabling rapid and sensitive detection. This assay is intended for use in central laboratories to support clinical toxicology evaluations.

  • How is the RapidFRET Oral Fluid Assay supplied and what does it include?

    The assay is supplied as a ready-to-use system, including the RapidFRET Oral Fluid Assay for Cocaine itself, along with a calibrator set and a control set. These components are essential for validating the assay’s performance and ensuring accurate results. The system is specifically designed to operate on the RapidFRET Integrated Workstation.

  • Is the RapidFRET Oral Fluid Assay single-use or reusable?

    The RapidFRET Oral Fluid Assay follows standard immunoassay protocols, which means it is intended for single-use only. Each assay kit is designed for one-time use to maintain accuracy and reliability, preventing cross-contamination or degradation of results from repeated use.

  • What regulatory clearance does the RapidFRET Oral Fluid Assay hold?

    The RapidFRET Oral Fluid Assay for Cocaine, along with its calibrator and control sets, holds a 510(k) clearance (K142129) from the FDA, demonstrating substantial equivalence to a predicate device. This clearance confirms its compliance with FDA regulations under 21 CFR 862.3250 and its classification as a Class II medical device.

  • How does the assay’s fluorescence technology improve detection?

    The assay employs a homogeneous time-resolved fluorescence (TRF) method, where competitive binding occurs between an antibody conjugated to a donor fluorophore and cocaine conjugated to an acceptor fluorophore. When cocaine or its metabolites are present, they compete with the labeled cocaine, reducing fluorescence signal. This technology allows for rapid, sensitive, and specific detection without the need for separation steps, improving both efficiency and accuracy in clinical settings.